• Revenue: $126.9 million, up 23.5% year-over-year.
• Annualized Recurring Revenue (ARR): $493.9 million, up 22.7% year-over-year.
• Adjusted EBITDA: $45.1 million, representing 35.5% of revenue, up 40% year-over-year.
• Gross Margin: 78.9%, a 370 basis point improvement from fiscal year 2022.
• GAAP Net Income: $6.9 million.
• Free Cash Flow: $23 million, up 168% year-over-year.
• Total Cash and Cash Equivalents: $282.9 million.
• Net Revenue Retention Rate: 114%.
• Equity-Based Compensation: $27.6 million, 21.7% of Q1 revenue.
• R&D Expense: $37.4 million, 21.6% of revenue on a non-GAAP basis.

• Warning! GuruFocus has detected 6 Warning Signs with CWAN.

Release Date: April 30, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Clearwater Analytics Holdings Inc (NYSE:CWAN) reported strong revenue growth of 23.5% year-over-year, reaching $126.9 million for Q1 2025.
• The company achieved a record high gross margin of 78.9%, showing significant improvement from previous years.
• Adjusted EBITDA for Q1 2025 was $45.1 million, representing a 35.5% margin and a 40% increase year-over-year.
• The company has a high client retention rate with a gross revenue retention rate of 98% and a net revenue retention rate of 114%.
• Strategic acquisitions of Enfusion, Beacon, and Bistro are expected to enhance Clearwater's platform, offering a comprehensive cloud-native investment management solution.

Negative Points

• The net revenue retention rate decreased slightly from 116% in the previous quarter to 114% in Q1 2025, indicating a slight reduction in client expansion.
• Equity-based compensation expenses remain high, representing 21.7% of Q1 revenue.
• The integration of recent acquisitions may pose challenges and could take time to realize expected synergies and growth acceleration.
• The company faces potential macroeconomic risks that could impact future growth, as indicated by the cautious guidance provided.
• There is a 15% dilution in shares due to recent acquisitions, which may affect shareholder value in the short term.

Q & A Highlights

Q: Can you provide guidance on how we should think about revenue growth for 2026 and 2027? A: Jim Cox, CFO, explained that Clearwater aims for a 20% growth rate, and they expect Enfusion's growth to accelerate from 13% to 20% over the next two years. The company is committed to expanding EBITDA margins by 200 basis points annually.

Q: How does Bistro fit into the integration with Beacon and Enfusion? A: Sandeep Sahai, CEO, stated that Bistro provides visualization capabilities for alternative assets, applicable across asset management, hedge funds, and insurance companies. It is seen as a horizontal capability that will be integrated with Clearwater's and Enfusion's client bases.

Q: What are you seeing in terms of demand and macroeconomic impacts on the business? A: Sandeep Sahai noted that while asset prices have generally declined, Clearwater's revenue remains solid due to its resilient business model. Jim Cox added that while there was a slight decrease in net revenue retention, the company is well-protected against macroeconomic headwinds.

Q: How quickly can you achieve synergies from the acquisitions of Enfusion and Beacon? A: Sandeep Sahai expressed confidence in achieving cost synergies, including a 400 basis point gross margin improvement in the first year and $20 million in cost savings. Many synergies related to G&A have already been implemented.

Q: Can you provide insights into the hedge fund market and Enfusion's performance? A: Jim Cox highlighted that Enfusion's churn has stabilized, and the company is focusing on hedge fund conversions. Sandeep Sahai added that Enfusion's migration away from smaller hedge funds has made the business stickier, contributing to stable churn levels.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.